Gene Delivery Technologies Global Market Opportunities and Strategies to 2033

This report describes and explains the gene delivery technologies market and covers 2018-2023, termed the historic period, and 2023-2028, 2033F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global gene delivery technologies market reached a value of nearly $3.3 billion in 2023, having grown at a compound annual growth rate (CAGR) of 8.87% since 2018. The market is expected to grow from $3.3 billion in 2023 to $6.4 billion in 2028 at a rate of 14.12%. The market is then expected to grow at a CAGR of 14.67% from 2028 and reach $12.7 billion in 2033.

Growth in the historic period resulted from increase in demand for agricultural products, the growing construction industry and the rising demand for paper and ceramic products. Factors that negatively affected growth in the historic period was availability of substitutes in the paper industry.

Going forward, the increasing demand from the cosmetic industry, the growing investments in infrastructure projects and the rising adoption of gene delivery technologies in medical formulations will drive the growth. Factor that could hinder the growth of the gene delivery technologies market in the future include fluctuating raw material prices and regulatory constraints.

The gene delivery technologies market is segmented by mode into biological, chemical and physical. The biological market was the largest segment of the gene delivery technologies market segmented by mode, accounting for 59.26% or $2 billion of the total in 2023. Going forward, the chemical segment is expected to be the fastest growing segment in the gene delivery technologies market segmented by mode, at a CAGR of 15.63% during 2023-2028.

The gene delivery technologies market is segmented by application into gene therapy, cell therapy, vaccines and research. The gene therapy market was the largest segment of the gene delivery technologies market segmented by application, accounting for 37.01% or $1.2 billion of the total in 2023. Going forward, the cell therapy segment is expected to be the fastest growing segment in the gene delivery technologies market segmented by application, at a CAGR of 15.79% during 2023-2028.

The gene delivery technologies market is segmented by method into ex vivo, in vivo and in vitro. The ex vivo market was the largest segment of the gene delivery technologies market segmented by method, accounting for 44.52% or $1.5 billion of the total in 2023. Going forward, the in vivo segment is expected to be the fastest growing segment in the gene delivery technologies market segmented by method, at a CAGR of 15.34% during 2023-2028.

North America was the largest region in the gene delivery technologies market, accounting for 41.53% or $1.4 billion of the total in 2023. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the gene delivery technologies market will be Asia Pacific and North America where growth will be at CAGRs of 15.31% and 14.62% respectively. These will be followed by South America and Western Europe where the markets are expected to grow at CAGRs of 14.02% and 12.83% respectively.

The global gene delivery technologies market is highly concentrated, with large players operating in the market. The top ten competitors in the market made up to 67.3% of the total market in 2022. The market concentration can be attributed to the presence of large number of players in different geographies. Prominent players are acquiring the products and entering into partnerships with the other companies to consolidate their market positions across the globe, while others are distributing products. Horizon Discovery Group Co was the largest competitor with a 37.4% share of the market, followed by Bio-Rad Laboratories Inc. with 13.9%, Promega Corporation with 7.2%, OriGene Technologies Inc. with 2.3%, Takara Bio Inc. with 2.3%, QIAGEN NV with 2.1%, Oxford Biomedica Solutions LLC with 1.5%, Sirion-Biotech GmbH with 0.2%, SignaGen Laboratories LLC with 0.2% and System Biosciences LLC with 0.1%.

The top opportunities in the gene delivery technologies market segmented by mode will arise in the biological segment, which will gain $1.8 billion of global annual sales by 2028. The top opportunities in the gene delivery technologies market segmented by method will arise in the ex vivo segment, which will gain $1.3 billion of global annual sales by 2028. The top opportunities in the gene delivery technologies market segmented by application will arise in the gene therapy segment, which will gain $1.1 billion of global annual sales by 2028. The gene delivery technologies market size will gain the most in the USA at $1.1 billion.

Market-trend-based strategies for the gene delivery technologies market include strategic partnerships for enhanced gene delivery technologies production, strategic collaborations for emission reduction initiatives and gene delivery technologies exploration projects for resource expansion and rare earth element discoveries.

Player-adopted strategies in the gene delivery technologies market include focus on collaboration and partnerships to enhance the precision of diagnostics, strengthening business capabilities through licensing and product development agreements, expanding business capabilities through product launches and strengthening business capabilities through product development and approval.

To take advantage of the opportunities, the analyst recommends the gene delivery technologies companies to focus on advancing gene editing tools, focus on expanding gene therapy product portfolio, focus on chemical market segment growth, focus on in vivo market segment growth, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for distribution expansion, provide competitively priced offerings, participate in trade shows and events, prioritize educational content creation and focus on targeted end-user engagement.